marketwatch_top

SpaceX may face an easier path to S&P 500 entry if these newly proposed rules take hold

spacex, anthropic and openai are reportedly preparing for ipos, and s&p dow jones indices is considering rule changes that could make it easier for them to join the s&p 500. the proposed changes include a "fast-track" entry process and looser profitability requirements.

currently, companies need to show four consecutive quarters of positive earnings to qualify. the new rules would let the index committee waive that for certain large, newly public firms — potentially clearing a path for spacex, which has never posted a profit. anthropic and openai, both burning cash on ai development, would also benefit.

s&p dow jones hasn't made a final decision yet. but the timing lines up: spacex is reportedly targeting a 2025 ipo, and both ai firms are weighing public listings as well.

source: marketwatch_top
sentiment: +0.30 · impact: 0.60

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds